COO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cooper Companies Inc (COO) is not a strong buy for a beginner investor with a long-term strategy at this time. While the technical indicators are relatively neutral to slightly bullish, the company's recent financial performance shows declining net income, EPS, and gross margin. Additionally, there are no strong positive catalysts or recent news to drive significant upside in the near term. Analyst ratings are mixed, with some concerns about future competition impacting earnings. Given the lack of strong signals and the user's preference for long-term investment, holding off on buying COO at this time is recommended.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 51.839, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock price is near its pivot level (81.086) with support at 79.386 and resistance at 82.786. However, the stock's recent price change (-1.63% in the regular market and -0.50% post-market) suggests a lack of momentum.
The company reported better-than-expected fiscal Q4 2025 revenue and EPS, with some analysts noting stabilizing growth trends in its Vision and Surgical segments. Analysts have raised price targets slightly, indicating moderate confidence in the stock's performance.
Analysts have expressed concerns about potential competition from Sebela's Miudella launch in mid-2026, which could pressure COO's Paragard sales and earnings. Additionally, there are no significant hedge fund or insider trading trends, and no recent news to act as a catalyst.
In Q4 2025, revenue increased by 4.59% YoY to $1.065 billion. However, net income dropped by 28% YoY to $84.6 million, EPS fell by 27.12% YoY to $0.43, and gross margin declined by 8.42% YoY to 56.43%. These figures indicate declining profitability despite revenue growth.
Analyst ratings are mixed. Needham lowered its price target to $99 and highlighted potential competitive risks, while Barclays and others raised price targets slightly (to $98, $95, etc.) and maintained positive ratings. Goldman Sachs remains bearish with a Sell rating and a price target of $73, citing concerns about organic growth and valuation.
